Table 1

Baseline demographics and disease characteristics (FAS)

Study population (n=76)
Gender: male, n (%)26 (34)
Mean (SD) age, years54.4 (10.9)
Mean (SD) body mass index, kg/m225.1 (3.8)
Mean (SD) time since first diagnosis, years6.0 (6.2)
Mean (SD) estimated duration of CD, years9.2 (7.2)
Pretreated with BT for CD, n (%)*57 (75)
 Mean (SD) number of injection sessions22.4 (20.7)
 Mean (SD) time since start of treatment, years6.8 (5.5)
Mean (SD) TWSTRS scores at study baseline
 Total39.0 (10.3)
 Severity18.3 (3.8)
 Disability11.2 (5.1)
 Pain9.5 (4.9)
Mean (SD) DDS score at study baseline†72.2 (26.2)
Swallowing difficulties at study baseline‡ (dysphagia scale score >0), n (%)7 (9)
  • *Formulations received at the last injection session prior to study entry were incobotulinumtoxinA (n=32), abobotulinumtoxinA (n=14) or onabotulinumtoxinA (n=11).

  • †Baseline DDS scores were available for 71 patients.

  • ‡The number of patients with swallowing difficulties at study baseline was based on the safety evaluation set (n=76).

  • BT, botulinum toxin; CD, cervical dystonia; DDS, Dystonia Discomfort Scale; FAS, full analysis set; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.